10th Nov 2026 07:00
TM
Renalytix plc
(“Renalytix” or the “Company”)
Conference attendance at Mello2026 Investor event
LONDON and NEW YORK, 10 November 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that Renalytix will be presenting and exhibiting at the Mello2026 investor event on Tuesday 17 November, which will be held at The Clayton Hotel & Conference Centre, Chiswick High Road, London, W4 5RY.
James McCullough, CEO, will be presenting at 11:50am and 16:10pm on the day, providing an overview of the Company and strategy. A PDF copy of the presentation will be made available on the Company’s website at https://investors.renalytix.com/.
For further information and tickets for the Mello2026 conference, please visit the event website at https://www.melloevents.com/mellolondon2026.
For further information, please contact:
Renalytix plc | www.renalytix.com | |
James McCullough, CEO | Via Walbrook PR | |
|
| |
SP Angel Corporate Finance LLP (Nominated Adviser, Joint Broker) | Tel: +44 (0)20 3470 0470 | |
David Hignell / Jen Clarke (Corporate Finance) |
| |
Vadim Alexandre (Corporate Broking) |
| |
|
| |
Oberon Capital (Joint Broker) | Tel: +44 (0)20 3179 5300 | |
Mike Seabrook / Heena Karani |
| |
|
| |
Walbrook PR Limited | Tel: +44 (0)20 7933 8780 or [email protected] | |
Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
About kidneyintelX.dkd and RenalytixTM (www.kidneyintelx.com and www.renalytix.com)
RenalytixTM (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. Its KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.
Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to reducing suffering and controlling cost in the United States and United Kingdom medical systems, affecting approximately 15 million and 8 million people, respectively.
RenalytixTM has been granted FDA authorization and Medicare reimbursement for kidneyintelX.dkd which is offered commercially throughout the United States. For more information about the kidneyintelX.dkd test, visit www.kidneyintelx.com.
Related Shares:
Renalytix Plc